SRPX

Across TCGA pan-cancer cohorts, SRPX mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SRPX’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SRPX mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SRPX is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

COAD, HNSC, and LSCC are the cancer types where SRPX tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRPX mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	−1.621	<.001	11	view →
HNSC	Male	IV	−1.322	<.001	11	view →
LSCC	Female	II,III,IV	−1.321	<.001	9	view →
LUAD	Female	III,IV	−1.302	<.001	9	view →
PDAC	All	All	+0.460	<.001	6	view →
OV	All	All	−2.181	<.001	2	view →
CCRCC	Male	III,IV	−0.607	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SRPX–COAD

Open the COAD breakdown →